The Kidneys Count campaign provides educational content and resources to help people understand the importance of kidney health and of prevention, early detection and management of kidney disease.

Mirum Pharmaceuticals MIRM reported a loss of 11 cents per share in fourth-quarter 2025, against the Zacks Consensus Estimate ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended ...

In an effort to battle against what members feel is an existential threat to their business, a group of 10 domestic biotech companies have launched the Midsized Biotech Alliance of America with a ...

Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. Read more on TVTX stock here.

Travere Therapeutics Inc. (NASDAQ: TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, ...

NORD Calls on Nation to "Show Your Stripes®" on Global Rare Disease Day®, Feb. 28NORWELL, Mass., Feb. 23, 2026 /PRNewswire/ - ...

Travere Therapeutics (TVTX) is back in focus after Q4 2025 results topped earnings expectations, supported by record demand for FILSPARI, with investors also weighing recent FDA approvals and late ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...

FILSPARI generated $103.3 million in U.S. net product sales for Q4 and $322 million for the full year. Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 and $88.5 ...